Antisecretory Factor Glioblastoma Phase 2

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Glioblastoma

In brief

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Key facts

Study ID

NCT05669820

Run by

Peter Siesjö

People needed

300

Starts

2024-01-15

Expected to finish

2027-12-01

Last updated by the study team

2026-01-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathology verified glioblastoma or astrocytoma grade 4
• Age 18-75 years
• Surgical treatment-resection.
• Scheduled concomitant radiochemotherapy, or only chemotherapy.
• Informed consent

You may not qualify if…

• No informed consent
• Egg yolk allergy
• Only surgical biopsy
• Only radiotherapy

Where it is running

• Skåne University Hospital — Lund, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.